Aurobindo Pharma‘s shares experienced a surge in value as the company revealed its intention to launch a groundbreaking tablet aimed at treating HIV in low-to-middle income countries. The tablet, named pLAD, is set to provide a critical solution for children living with HIV, particularly those weighing between 6 kg and 25 kg and aged three months or older.
The pLAD tablet is the result of Aurobindo Pharma’s collaboration with Viv Healthcare, operating under a voluntary license. Comprising a combination of abacavir, dolutegravir, and lamivudine, this medication is designed to not only diminish viral presence in the body but also enhance the immune system while impeding the progression of HIV into AIDS.
The World Health Organisation has identified the pLAD dosage as a priority choice for children living with HIV. Its forthcoming generic approval holds the potential to make accessible and affordable HIV medication available to those residing in low-to-middle income countries. The plan includes the distribution of pLAD in 123 nations, encompassing India.
K Nithyananda Reddy, Vice-Chairman and Managing Director of Aurobindo Pharma, expressed enthusiasm regarding the approval, anticipating its positive impact on over a million children across these countries, subsequently amplifying treatment coverage.
Aurobindo Pharma’s recent success extended beyond this HIV initiative. The company attained USFDA approval for Icatibant injection on August 16. This injection addresses hereditary angioedema, a genetic ailment inducing swelling in various body parts such as the skin, airways, and digestive tract.
Headquartered in Hyderabad, Aurobindo Pharma is a global manufacturer of generic pharmaceuticals, active pharmaceutical ingredients, and branded specialty pharmaceuticals. Its influence extends across more than 150 countries worldwide.
For more updates stay tuned to FELA News!
